Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2004-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMA.292.1.45PMID 15238590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interventional cardiology: abstractEfficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: A systematic overview☆

  2004cited by this paper
• Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.

  2004cited by this paper
• Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.

  2004cited by this paper
• Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes: Exploration of Methods

  2004cited by this paper
• Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.

  2003cited by this paper
• Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide

  2003cited by this paper
• Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

  2003cited by this paper
• Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.

  2003cited by this paper
• The SYNERGY trial: study design and rationale.

  2002influential reference
• Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study☆☆☆★

  2002cited by this paper
• Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.

  2002cited by this paper
• ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients

  2002cited by this paper
• [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].

  2001cited by this paper
• Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

  2001cited by this paper
• Low Molecular Weight Heparin Therapy for Percutaneous Coronary Intervention: A Practice in Evolution

  2001cited by this paper
• Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

  2001cited by this paper
• Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.

  2000cited by this paper
• Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology.

  2000cited by this paper
• Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

  1999cited by this paper
• Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.

  1999cited by this paper
• Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.

  1999cited by this paper
• Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study

  1999cited by this paper
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

  1998cited by this paper
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

  1998cited by this paper
• A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

  1997cited by this paper
• A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

  1997cited by this paper

• Era to Action: 40 Years of Health Disparity Research in Cardiovascular Disease and the Path to Equity

  2025cites this paper
• The triple impact of Enoxaparin: Moderating comorbidities, reducing hospitalization, and rationalizing medications

  2025cites this paper
• Safety and efficacy of enoxaparin versus unfractionated heparins in conservatively managed patients with acute coronary syndrome: a systematic review

  2025cites this paper
• 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• Physicochemical Characteristics of Cardiological Drugs and Practical Recommendations for Intravenous Administration: A Systematic Review

  2025cites this paper
• Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?

  2025cites this paper
• Invited Article: Al guided Dual Antiplatelet Therapy and Anticoagulation.

  2025cites this paper
• Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75 Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison of Patients 60 to <75 Years in STREAM-1 and -2.

  2025cites this paper
• Comparison of Pretreatment in European Society of Cardiology Acute Coronary Syndrome Guidelines

  2025cites this paper
• 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025.

  2025cites this paper
• [Guidelines for the management of non-ST elevation acute coronary syndromes (2024)].

  2024cites this paper
• Safety and Efficacy of Enoxaparin During Low-Risk Elective Percutaneous Coronary Intervention.

  2024cites this paper
• Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China

  2024cites this paper
• Antithrombotic Therapy in Acute Coronary Syndrome.

  2024cites this paper
• Pre-hospital admission of heparin in patients with suspected non-ST segment elevation acute coronary syndrome

  2024cites this paper
• Enoxaparin Versus Unfractionated Heparin in Acute Coronary Syndrome Without St-Segment Elevation: A Systematic Review and Meta-Analysis

  2024cites this paper
• Role of anticoagulation in non-ST-elevation myocardial infarction: a contemporary narrative review

  2024cites this paper
• Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

  2023cites this paper
• Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era

  2023cites this paper
• 2023 ESC Guidelines for the management of acute coronary syndromes.

  2023cites this paper
• 2023 ESC Guidelines for the management of acute coronary syndromes.

  2023cites this paper
• Non-ST-Elevation Acute Coronary Syndromes

  2022cites this paper
• Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention

  2022cites this paper
• Percutaneous Coronary Interventions and Complications, Intra‐Aortic Balloon Pump, Ventricular Assist Devices, and Fractional Flow Reserve

  2022cites this paper
• The Evolution of Anticoagulation for Percutaneous Coronary Intervention:A 40-Year Journey.

  2022cites this paper
• Non‐ST‐Segment Elevation Acute Coronary Syndrome

  2022cites this paper
• Acute coronary syndrome without persistent elevation of the ST segment: New recommendations

  2022cites this paper
• 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2021cites this paper
• Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data

  2021cites this paper
• Síndrome coronario agudo sin elevación del segmento ST

  2021cites this paper
• Circulation: Cardiovascular Quality and Outcomes

  2021cites this paper
• Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS)

  2021cites this paper
• 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2021cites this paper
• The Smoker’s Paradox in Patient with Acute Coronary Syndrome: A Systemic Review

  2021cites this paper
• Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021

  2021cites this paper
• Anticoagulants Used in Cardiac Catheterization of Patients With Chronic Lymphocytic Leukemia: A Case Report and Overview

  2021influential citation
• Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials

  2021cites this paper
• Contemporary use of anticoagulation in the cardiac catheterization laboratory: a review

  2021cites this paper
• Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST

  2021cites this paper
• COVID‐19 pandemic: Challenges and solutions from the cardiology pharmacist's perspective

  2020cites this paper
• Das primeiras às mais recentes intervenções farmacológicas para síndromes coronarianas agudas

  2020influential citation
• Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome

  2020cites this paper
• 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

  2020cites this paper
• Research Trends in Anticoagulation Therapy over the Last 25 Years

  2020cites this paper
• Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.

  2019cites this paper
• Anticoagulation in Acute Coronary Syndrome: Review of Major Therapeutic Advances

  2019cites this paper
• Antithrombotic therapy in the early phase of NSTE-ACS: a systematic review and meta-analysis.

  2019cites this paper
• Anticoagulation

  2019cites this paper
• Intervención coronaria en pacientes con fibrilación auricular

  2019cites this paper
• Association of Parenteral Anticoagulation Therapy With Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention for Non–ST-Segment Elevation Acute Coronary Syndrome

  2019cites this paper
• UNSTABLE ANGINA AND NON-ST ELEVATION MYOCARDIAL INFARCTION: TREATMENT AND PROGNOSIS

  2019cites this paper
• 2018 ESC/EACTS Guidelines on myocardial revascularization.

  2019cites this paper
• Guía ESC/EACTS 2018 sobre revascularización miocárdica

  2019cites this paper
• Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives.

  2019cites this paper
• Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial

  2019cites this paper
• From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes: JACC State-of-the-Art Review.

  2019cites this paper
• Anticoagulant acrobatics: Surviving the global heparin shortage in the emergency department.

  2019cites this paper
• 2018 ESC/EACTS Guidelines on myocardial revascularization.

  2018cites this paper
• Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review

  2018cites this paper
• Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention

  2018cites this paper
• Discharge timing and outcomes after uncomplicated non–ST‐segment elevation acute myocardial infarction

  2018cites this paper
• Edinburgh Explorer Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes

  2018cites this paper
• First 24 h in the management of non-ST segment elevation myocardial infarction

  2018cites this paper
• Unfractionated Heparin and Low-Molecular-Weight Heparin

  2018cites this paper
• The Evolving Face of Myocardial Reperfusion in Acute Coronary Syndromes: A Primer for the Internist

  2018cites this paper
• [2018 ESC/EACTS Guidelines on myocardial revascularization].

  2018cites this paper
• Bleeding Associated with Angiography and Percutaneous Coronary Intervention

  2018cites this paper
• Bivalirudin Bivalirudin – aus dem Forschungs-in das Herzkatheterlabor

  2018cites this paper
• ANGINA INSTÁVEL E INFARTO AGUDO DO MIOCÁRDIO SEM SUPRADESNIVELAMENTO DE ST: TRATAMENTO E PROGNÓSTICO

  2018cites this paper
• 2018 ESC/EACTS Guidelines on myocardial revascularization.

  2018cites this paper
• Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention

  2018cites this paper
• Acute Coronary Syndrome

  2018cites this paper
• Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin

  2018cites this paper
• 2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome.

  2018cites this paper
• Antiplatelet and anticoagulation therapy during percutaneous coronary interventions: A review for the interventionalist

  2018cites this paper
• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

  2018cites this paper
• Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention

  2018cites this paper
• Bleeding Severity After Percutaneous Coronary Intervention

  2018cites this paper
• Gender differences in the effects of cardiovascular drugs

  2017cites this paper
• M 118 – A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes

  2017cites this paper
• Eingriffe unter NOAK

  2017cites this paper
• Farmakoterapija akutnog infarkta miokarda

  2017cites this paper
• Just Because Things Are Not Different, Does Not Mean They Are the Same: Biomarker Patterns in Acute Respiratory Distress Syndrome.

  2017cites this paper
• Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention.

  2017cites this paper
• Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes

  2017cites this paper
• Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pharmacologic pre-treatment for patients undergoing

  2017cites this paper
• Anticoagulants in ischemia‐guided management of non‐ST‐elevation acute coronary syndromes

  2017cites this paper
• Peri- and Post-procedural Antithrombotic Therapy in Women

  2017cites this paper
• Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention

  2017cites this paper
• Anticoagulant Therapy for Acute Coronary Syndromes.

  2017cites this paper
• Prosthetic Mitral Surgical Valve in Transcatheter Aortic Valve Replacement Recipients: A Multicenter Analysis.

  2017cites this paper
• Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.

  2016cites this paper
• Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.

  2016cites this paper
• Anticoagulation in coronary intervention.

  2016cites this paper
• Controversies in cardiovascular medicine Anticoagulation in coronary intervention

  2016cites this paper
• Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism

  2016cites this paper
• Grupo de Trabajo de Revascularización Miocárdica de la Sociedad Europea de Cardiología (ESC) y la European Association for Cardio-Thoracic Surgery (EACTS) Desarrollada con la colaboración especial de la European Association of Percutaneous Cardiovascular Interventions (EAPCI)

  2016cites this paper
• Recomendaciones para el diagnostico y tratamiento del sõ´ndrome coronario agudo sin elevacion del segmento ST

  2016cites this paper
• Anticoagulation in Acute Coronary Syndromes

  2016cites this paper